Changes in the Epidemiology of Hepatitis A Outbreaks 13 Years After the Introduction of a Mass Vaccination Program
Overview
Authors
Affiliations
A hepatitis A+B vaccine vaccination program of 12-year-olds was introduced in Catalonia in 1998. The aim of this study was to investigate the evolution of hepatitis A outbreaks in Catalonia and estimate the preventable fraction of cases associated with outbreaks as a measure of the impact of the vaccination program. Hepatitis A outbreaks reported to the Health Department between 1991 and 2012 were analyzed. The incidence rates of outbreaks, outbreak-associated cases and hospitalizations were calculated. The preventable fraction (PF) and 95% confidence intervals (CI) were estimated for the whole study period (pre-vaccination and post-vaccination) and the post-vaccination period. One-hundred-eight (108) outbreaks (rate of 2.21 per 10(6) persons-year) were reported in the pre-vaccination period and 258 outbreaks (rate of 2.82 per 10(6) persons-year) in the post-vaccination period. The rate of cases associated with outbreaks was 1.52 per 10(5) persons-year in the pre-vaccination period and 1.28 per 10(5) persons-year in the post-vaccination period. Hospitalization rates were 0.08 and 0.75 per 10(6) persons-year, respectively. The number of person-to-person outbreaks whose index case was a school contact decreased in the post-vaccination period (aOR 2.72; 95%CI 1.35-5.48), but outbreaks whose index case was a man who has sex with men (MSM) or an immigrant increased. The PF of all outbreak-associated cases was 6.46% (95%CI 3.11-9.82) and the highest PF was in the 15-24 years age group (42.53%; 95%CI 29.30-55.75). In the 0-4 years age group, the PF was 18.35% (95%CI 9.59-27.11), suggesting a protective herd effect in unvaccinated subjects. Vaccination of immigrants traveling to endemic countries and MSM should be reinforced.
Yigit M, Kalayci F BMC Infect Dis. 2025; 25(1):61.
PMID: 39810097 PMC: 11734540. DOI: 10.1186/s12879-025-10458-9.
Herzog C, Van Herck K, Van Damme P Hum Vaccin Immunother. 2020; 17(5):1496-1519.
PMID: 33325760 PMC: 8078665. DOI: 10.1080/21645515.2020.1819742.
Mellou K, Chrysostomou A, Sideroglou T, Kyritsi M, Georgakopoulou T, Tsiodras S Epidemiol Infect. 2020; 148:e58.
PMID: 32052723 PMC: 7078582. DOI: 10.1017/S0950268820000382.
Human immunodeficiency virus and liver disease: A comprehensive update.
Sherman K, Peters M, Thomas D Hepatol Commun. 2019; 1(10):987-1001.
PMID: 30838978 PMC: 5721407. DOI: 10.1002/hep4.1112.
Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine.
Van Damme P, Leroux-Roels G, Suryakiran P, Folschweiller N, Van Der Meeren O Hum Vaccin Immunother. 2017; 13(5):972-980.
PMID: 28281907 PMC: 5443376. DOI: 10.1080/21645515.2016.1274473.